Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNantes University Hospital

About this trial

Congenital heart defects (CHD), as the leading cause of birth defects, affect 12 million people globally and approximately 41,000 newborns each year in Europe. CHD presents a significant public health concern due to its association with high morbidity and mortality rates across the lifespan. Over 50% of infants born with critical CHD will develop neurodevelopmental disorders (NDD), requiring specialized care and impacting their quality of life. NDDs, involving early and persistent disruptions in cognitive, emotional, and behavioral development due to abnormal brain development, are highly variable. They may impact language, learning, motor skills, intellectual efficiency, social cognition, attention, memory, and executive functions, often accompanied by psychosocial difficulties. These hidden disabilities constitute the primary long-term sequelae of CHD, surpassing even cardiovascular complications in impact, and affect children who often undergo multiple cardiac surgeries during early childhood. NDDs are associated not only with complex CHDs but also with simpler CHDs that are repaired in early childhood and considered 'cured.'

The origin of CHD-associated NDDs remains largely unknown. While few genetic or environmental causes have been identified, recent research suggests a possible common origin linking heart malformations and neurodevelopmental abnormalities. The CATAMARAN neonatal cohort project aims to detect developmental delays associated with CHD as early as six months of age and to identify both individual susceptibility factors and acquired vulnerabilities contributing to the development of NDDs in infants with CHD.

Eligibility criteria

Qualifiers

Fetus with a congenital heart defect (CHD) detected prenatally (prenatal diagnosis of the heart defect)

Fetus with a critical CHD defined as requiring cardiac surgery during the first three months of the infant's life

Parents affiliated with or beneficiaries of a social security or equivalent system

Parents' good understanding of the French language

Disqualifiers

Medical termination of pregnancy considered

Genetic anomaly or malformative syndrome identified prior to inclusion

Trial design

Treatments tested in this trial

  • Neurodevelopmental assessment (Bayley-IV)
  • Biological sampling
  • ELFE dietary questionnaire
  • Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)
  • Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)

Treatment groups

450 Participants
are divided into 1 treatment group

Sponsors and collaborators

Nantes University Hospital

Lead sponsor

Pays de la Loire Laboratory of Psychology (LPPL)

Collaborator

Physiopathology of Nutritional Adaptations Joint Research Unit (UMR PhAN)

Collaborator

Institut du thorax, INSERM UMR1087

Collaborator